Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03916627 |
| Title | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Regeneron Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | RECRUITING | New York | New York | 10029 | United States | Details |